Claims for Patent: 8,974,776

Summary for Patent: 8,974,776

Title:	Biodegradable peptide releasing polymers
Abstract:	Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.
Inventor(s):	Stopek; Joshua B. (Yalesville, CT), Cuevas; Brian (Cumming, GA)
Assignee:	Covidien LP (Mansfield, MA)
Application Number:	12/599,772
Patent Claims:	1. A biodegradable composition comprising: at least one hydroxyl-terminated component; and at least one bioactive peptide, wherein the biodegradable composition comprises a linear chain of the formula (AB).sub.nwherein A is the at least one bioactive peptide, B is the at least one hydroxyl-terminated component, and n is a number from about 5 to about 500, and degradation of the at least one hydroxyl-terminated component releases the bioactive peptide in vivo, and wherein the biodegradable composition further comprises at least one medicinal agent selected from the group consisting of antimicrobial agents, colorants, preservatives, protein preparations, peptide preparations, antipyretic agents, antiphlogistic agents, analgesic agents, anti-inflammatory agents, vasodilators, antihypertensive agents, antiarrhythmic agents, hypotensive agents, antitussive agents, antineoplastics, local anesthetics, hormone preparations, antiasthmatic agents, antiallergic agents, antihistaminics, anticoagulants, antispasmodics, cerebral circulation improvers, metabolism improvers, antidepressant agents, antianxiety agents, vitamin D preparations, hypoglycemic agents, antiulcer agents, hypnotics, antibiotics, antifungal agents, sedative agents, bronchodilator agents, antiviral agents, dysuric agents, and combinations thereof. 2. The biodegradable composition of claim 1, wherein the at least one hydroxyl-terminated component is selected from the group consisting of polyesters, and poly(ether-esters). 3. The biodegradable composition of claim 1, wherein the at least one hydroxyl-terminated component comprises a polyester selected from the group consisting of trimethylene carbonate, .epsilon.-caprolactone, p-dioxanone, glycolide, lactide, 1,5-dioxepan-2-one, polybutylene adipate, polyethylene adipate, polyethylene terephthalate, polymers thereof, and copolymers thereof. 4. The biodegradable composition of claim 1, wherein the at least one hydroxyl-terminated component comprises a poly(ether-ester) block selected from the group consisting of polyethylene glycol-polycaprolactone, polyethylene glycol-polylactide, polyethylene glycol-polyglycolide, polyethylene glycol-lactide-glycolide, polyethylene glycol-lactide-caprolactone, polyethylene glycol-trimethylene carbonate, polyethylene glycol-trimethylene carbonate-lactide, polyethylene glycol-trimethylene carbonate-glycolide, polyethylene glycol-trimethylene carbonate-caprolactone, and polyethylene glycol-glycolide-caprolactone. 5. The biodegradable composition of claim 1, wherein the at least one bioactive peptide is selected from the group consisting of coagulation modulators, cytokines, endorphins, kinins, hormones, extracellular matrix peptides, peptides containing an RGD motif, antimicrobial peptides, angiogenic peptides, anti-tumoral peptides, cell adhesion inhibitors, cell activation inhibitors, and combinations thereof. 6. The biodegradable composition of claim 1, wherein the at least one bioactive peptide comprises a coagulation modulator selected from the group consisting of .alpha..sub.1-antitrypsin, .alpha..sub.2-macroglobulin, antithrombin III, fibrinogen, prothrombin, tissue prothrombin, proaccelerin, proconvertin, antihemophilic globulin, plasma thromboplastin component, Stuart-Power factor, plasma thromboplastin antecedent, Hageman factor, heparin cofactor II, kallikrein, plasmin, plasminogen, prekallikrein, protein C, protein S, thrombomodulin, and combinations thereof. 7. The biodegradable composition of claim 1, wherein the at least one bioactive peptide comprises a cytokine selected from the group consisting of colony stimulating factor 4, heparin binding neurotrophic factor, interferon-.alpha., interferon .alpha.-2.alpha., interferon .alpha.-2b, interferon .alpha.-n3, interferon-.beta., interferon-.gamma., interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, tumor necrosis factor, tumor necrosis factor-.alpha., granuloycte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, midkine, thymopoietin, and combinations thereof. 8. The biodegradable composition of claim 1, wherein the at least one bioactive peptide comprises an endorphin selected from the group consisting of dermorphin, dynorphin, .alpha.-endorphin, .beta.-endorphin, .gamma.-endorphin, .SIGMA.-endorphin, [Leu.sup.5]enkephalin, [Met.sup.5]enkephalin, substance P, and combinations thereof. 9. The biodegradable composition of claim 1, wherein the at least one bioactive peptide comprises a kinin selected from the group consisting of bradykinin, bradykinin potentiator B, bradykinin potentiator C, kallidin, and combinations thereof. 10. The biodegradable composition of claim 1, wherein the at least one bioactive peptide comprises a peptide selected from the group consisting of activin, amylin, angiotensin, atrial natriuretic peptide, calcitonin, calcitonin gene-related peptide, calcitonin N-terminal flanking peptide, cholecystokinin, ciliary neurotrophic factor, adrenocorticotropin hormone, corticotropin-releasing factor, epidermal growth factor, follicle-stimulating hormone, gastrin, gastrin inhibitory peptide, gastrin-releasing peptide, ghrelin, glucogon, gonadotropin-releasing factor, growth hormone releasing factor, human chorionic gonadotropin, inhibin A, inhibin B, insulin, leptin, lipotropin, luteinizing hormone, luteinizing hormone-releasing hormone, buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide, lutrelin, nafarelin, tryptorelin, a-melanocyte-stimulating hormone, .beta.-melanocyte-stimulating hormone, .gamma.-melanocyte-stimulating hormone, melatonin, motilin, oxytocin, pancreatic polypeptide, parathyroid hormone, placental lactogen, prolactin, prolactin-release inhibiting factor, prolactin-releasing factor, secretin, somatotropin, somatostatin, thyroid-stimulating hormone, thyrotropin-releasing factor, thyroxine, triiodothyronine, vasoactive intestinal peptide, vasopressin and combinations thereof. 11. The biodegradable composition of claim 1, wherein the at least one bioactive peptide is selected from the group consisting of abarelix, adenosine deaminase, anakinra, ancestim, alteplase, alglucerase, asparaginase, bivalirudin, bleomycin, bombesin, desmopressin acetate, des-Q14-ghrelin, domase-.alpha., enterostatin, erythropoietin, exendin-4, fibroblast growth factor-2, filgrastim, .beta.-glucocerebrosidase, gonadorelin, hyaluronidase, IgG antibody fragments, insulinotropin, lactoferricin, lepirudin, magainin I, magainin II, nerve growth factor, neurofilament peptides, pentigetide, polylysine, telomerase inhibitors, thrombopoietin, thymosin .alpha.-1, thymidin kinase, tissue plasminogen activator, tryptophan hydroxylase, urokinase, urotensin II, and combinations thereof. 12. The biodegradable composition of claim 1, wherein the at least one bioactive peptide comprises a tissue-healing enhancing agent selected from the group consisting of glycosaminoglycans, proteoglycans, substrate adhesion molecules, polypeptide growth factors and combinations thereof. 13. A drug delivery device comprising the biodegradable composition of claim 1. 14. A method for delivering a bioactive peptide to an animal comprising administering the biodegradable composition of claim 1 to the animal. 15. A pharmaceutical composition comprising the biodegradable composition of claim 1 optionally in combination with a pharmaceutically acceptable carrier. 16. A surgical adhesive comprising the biodegradable composition of claim 1, optionally endcapped with a component selected from the group consisting of isocyanates, amines, hydroxyls, carboxyls, thiols, carbodiimidazoles, sulfonyl chlorides, chlorocarbonates, n-hydroxysuccinimidyl esters, succinimidyl esters, sulfasuccinimidyl esters, and combinations thereof. 17. A surgical sealant comprising the biodegradable composition of claim 1, optionally endcapped with an isocyanate. 18. A method comprising: polymerizing at least one cyclic monomer in the presence of a hydroxy functional peptide to form a copolymer; and recovering the resulting copolymer. 19. The method of claim 18, wherein the at least one cyclic monomer is selected from the group consisting of cyclic esters and cyclic carbonates. 20. The method of claim 18, wherein the at least one cyclic monomer comprises a cyclic ester selected from the group consisting of glycolide, L(-)-lactide, D(+)-lactide, meso-lactide, p-dioxanone, 1,4-dioxan-2-one, 1,5-dioxepan-2-one, epsilon-caprolactone, delta-valerolactone, gamma-butyrolactone, beta-propiolactone, and combinations thereof. 21. The method of claim 18, wherein at least one cyclic monomer comprises a cyclic carbonate selected from the group consisting of ethylene carbonate, trimethylene carbonate, dimethyl trimethylene carbonate, 3-ethyl-3-hydroxymethyl trimethylene carbonate, propylene carbonate, trimethylolpropane monocarbonate, 4,6 dimethyl-1,3-propylene carbonate, 2,2-dimethyl trimethylene carbonate, and 1,3-dioxepan-2-one, and combinations thereof. 22. The method of claim 18, wherein polymerizing the at least one cyclic monomer in the presence of the hydroxy functional peptide comprises heating the cyclic monomer and hydroxy functional peptide to a temperature of from about 170.degree. C. to about 185.degree. C., for a period of time from about 4 hours to about 6 hours. 23. The method of claim 18, further comprising heating the copolymer to a temperature from about 100.degree. C. to about 120.degree. C., for a period of time ranging from about 25 hours to about 35 hours. 24. A copolymer produced by the method of claim 18.

Details for Patent 8,974,776

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2027-05-14
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2027-05-14
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2027-05-14